CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.21, no.3, pp.147-153, 2021 (SCI-Expanded)
We retrospectively compared 47 acute lymphoblastic leukemia (ALL) patients who received Berlin-Frankfurt-Munster chemotherapy and 83 ALL. patients who underwent allogeneic hematopoietic stem-cell transplantation (AHSCT). While there was no difference in overall survival between the 2 groups, disease-free survival was found to be significantly higher in the AHSCT group.